Actinobacillus pleuropneumoniae vaccine vector |
|
Vaxvec ID |
27 |
|
Vaccine Vector Name |
Actinobacillus pleuropneumoniae vaccine vector |
|
Alternative Names |
Actinobacillus pleuropneumoniae HS93Tox- |
|
Vector VO ID |
VO_0001038
|
|
Function |
A. pleuropneumoniae is a causative agent of porcine pneumonia which affects pigs worldwide, and can cause great economic losses, so a vaccine preventing this disease would be good for economic as well as health reasons (Shin et al., 2013). |
|
Advantage |
The A. pleuropneumoniae toxin has been shown to partly induce immune responses, which is why its attenuated form is a good candidate for vaccine creation against porcine pneumonia (Prideaux et al., 1998). |
|
Disadvantage |
As well as inducing immune responses, the A. pleuropneumoniae toxin is also the cause of the bacterium's virulence (Prideaux et al., 1998). |
|
Preparation |
The HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector. A plasmid vector was created to express the ApxA gene inside the HS93Tox- mutant of A. pleuropneumoniae, so that the bacterium acts as a vector for its own natural toxin (Prideaux et al., 1998). |
|
Safety |
The A. pleuropneumoniae toxin ApxA must be shown to be attenuated in order to safely be inserted into a vector (which in turn, will "infect" the host) because otherwise the toxin is extremely virulent (Prideaux et al., 1998). |
|
Description |
A. pleuropneumoniae is a causative agent of porcine pneumonia which affects pigs worldwide, and can cause great economic losses. A mutant strain of A. pleuropneumoniae can be used as an effective vector for the transport of its own attenuated toxin (Prideaux et al., 1998). |
| Related Vaccine(s) |
|
| References |
Prideaux et al., 1998: Prideaux CT, Pierce L, Krywult J, Hodgson AL. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination. Current microbiology. 1998; 37(5); 324-332. [PubMed: 9767712].
Shin et al., 2013: Shin MK, Kang ML, Jung MH, Cha SB, Lee WJ, Kim JM, Kim DH, Yoo HS. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs. Veterinary immunology and immunopathology. 2013; 151(1-2); 132-139. [PubMed: 23206402].
|
